On the stock market since 1981, it operates in the world of health and science. It has 533 employees. Now — the numbers.
This is an established company with proven profits.
No real growth (4% a year).
If every debt were paid off today, $17.5M would still be left in the vault — a solid cushion for hard times.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
R&D Investment: Spending on future research is low.
The stock trades 18% below its peak. The market has trimmed its expectations for the company.
There is $56.5M in the vault; even if every debt were paid off, $17.5M would remain.
Over the last 3 years, sales grew only 2% a year on average. At this size, speeding back up is not easy.
The share set aside for the future is small; the pace of new ideas may slow. Council score: 2/10.
On our five-subject report card, FONR sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: FONR is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.